SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Mar 1, 2013–Regulatory News: MEDIAN Technologies (Paris:ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, announced today it has been selected as the imaging solutions provider in a new phase II clinical trial for a global biopharmaceutical company.
As part of the project, imaging data will be acquired in more than 100 clinical sites located in 14 countries worldwide. Anticipated total enrollment is 300 patients with a forecasted project start by year end.
Project amount is estimated at €1.4 M (eq. $1.8 M) for MEDIAN.
“ We are enthusiastic about this success. It provides further proof of our commitment to supply biopharma companies with the leading edge tools, expertise and services needed to increase productivity and improve patients’ lives. ” said Fredrik Brag, CEO of MEDIAN Technologies.
About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Quintiles, to offer integrated imaging services for clinical trials to customers worldwide.
Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (Current CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary.
For more information on MEDIAN, please visit: www.mediantechnologies.com
